Iker Huerga, SVP, Life Sciences Strategy and RWD at Tempus, discusses how heterogeneous data sources can strengthen clinical trial planning and execution to de-risk research.
We spoke with Gilead experts to learn how the company uses multimodal data to achieve early successes in translational biomarker research and discovery.
In this Q&A with Dr. Hisham Hamadeh of Genmab, we explore how using multimodal RWD can help organizations solve their toughest drug development challenges.
Go behind the scenes with Tempus COO Ryan Fukushima and learn how harmonized multimodal data sources help accelerate and de-risk drug development programs.
If you’re wondering how Tempus’s sequencing services can help your project move forward, consider the experiences of these four organizations, who partnered with Tempus for prospective sequencing for clinical trials, retrospective sequencing and analyses, companion diagnostic development, and sponsored testing.
Targeting discovery is an important frontier in the fight against pancreatic cancer. Take a look at this example of how the Tempus Multimodal Database enabled a pharmaceutical company to more quickly identify pancreatic cancer subtypes’ molecular signatures.
Combining sequencing, analytics, and data licensing with Tempus allows you to uncover new insights across the research and development spectrum. This case study shows how one company made it happen.